T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.
Antiviral Agents
/ pharmacology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ epidemiology
Cell Proliferation
Cross Reactions
/ immunology
Cytokines
/ metabolism
HEK293 Cells
Health Personnel
Humans
Immunoassay
/ methods
Immunoglobulin G
/ immunology
Immunologic Memory
Interferon-gamma
/ metabolism
Pandemics
Peptides
/ metabolism
SARS-CoV-2
/ drug effects
T-Lymphocytes
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
02
10
2020
accepted:
15
02
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
14
4
2021
Statut:
epublish
Résumé
Identification of protective T cell responses against SARS-CoV-2 requires distinguishing people infected with SARS-CoV-2 from those with cross-reactive immunity to other coronaviruses. Here we show a range of T cell assays that differentially capture immune function to characterise SARS-CoV-2 responses. Strong ex vivo ELISpot and proliferation responses to multiple antigens (including M, NP and ORF3) are found in 168 PCR-confirmed SARS-CoV-2 infected volunteers, but are rare in 119 uninfected volunteers. Highly exposed seronegative healthcare workers with recent COVID-19-compatible illness show T cell response patterns characteristic of infection. By contrast, >90% of convalescent or unexposed people show proliferation and cellular lactate responses to spike subunits S1/S2, indicating pre-existing cross-reactive T cell populations. The detection of T cell responses to SARS-CoV-2 is therefore critically dependent on assay and antigen selection. Memory responses to specific non-spike proteins provide a method to distinguish recent infection from pre-existing immunity in exposed populations.
Identifiants
pubmed: 33824342
doi: 10.1038/s41467-021-21856-3
pii: 10.1038/s41467-021-21856-3
pmc: PMC8024333
doi:
Substances chimiques
Antiviral Agents
0
Cytokines
0
Immunoglobulin G
0
Peptides
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2055Subventions
Organisme : Wellcome Trust
ID : 110110/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20002
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108869/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT109965MA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011233/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205228/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220171/Z/20/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 109965/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V028448/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19059
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L018942/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR200907
Pays : United Kingdom
Investigateurs
Jeremy Chalk
(J)
Georgina Kerr
(G)
Prabhjeet Phalora
(P)
Anna Csala
(A)
Mathew Jones
(M)
Nicola Robinson
(N)
Rachael Brown
(R)
Claire Hutchings
(C)
Nicholas Provine
(N)
Jeremy Ratcliff
(J)
Ali Amini
(A)
Martyna Borak
(M)
Stavros Dimitriadis
(S)
Thomas Fordwoh
(T)
Bryn Horsington
(B)
Sile Johnson
(S)
Jordan Morrow
(J)
Yolanda Warren
(Y)
Charlie Wells
(C)
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Infect Dis. 2021 Feb 13;223(3):409-415
pubmed: 32692346
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Euro Surveill. 2020 Oct;25(42):
pubmed: 33094713
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004152
pubmed: 26495852
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Clin Vaccine Immunol. 2010 Dec;17(12):1875-80
pubmed: 20943876
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Eur J Immunol. 2017 Oct;47(10):1584-1797
pubmed: 29023707
Sci Transl Med. 2014 Nov 5;6(261):261ra153
pubmed: 25378645
Immunity. 2013 Feb 21;38(2):373-83
pubmed: 23395677
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Cytometry A. 2008 Oct;73(10):926-30
pubmed: 18752282
Elife. 2020 Aug 21;9:
pubmed: 32820721
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Wellcome Open Res. 2020 Jun 11;5:139
pubmed: 33748431
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
J Exp Med. 2016 Jun 27;213(7):1331-52
pubmed: 27242166
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
J Infect Dis. 2018 May 5;217(11):1728-1739
pubmed: 29741740
Clin Vaccine Immunol. 2008 Dec;15(12):1805-10
pubmed: 18945884
J Immunol. 2018 Feb 1;200(3):1220-1226
pubmed: 29288205
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
J Exp Med. 2014 Jun 30;211(7):1273-80
pubmed: 24958850
BMC Infect Dis. 2013 Sep 16;13:433
pubmed: 24040960